Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third Quarter Conference Calls, In Brief

Executive Summary

Novartis Prexige launch delay?: Novartis anticipates launch of COX-2 inhibitor Prexige (lumiracoxib/COX-189) could be delayed until 2004. "We have here left a range for the launch. It is too early to speculate what the scientific and regulatory environment will be 15 months from now," Clinical R&D Head James Shannon says. "It is possible that we will have a straight 12-month review, and we could get approval at the end of 2003, but we feel it is conservative and gives a better indication, a better guidance, that we place the launch somewhere in 2004." Novartis plans to submit an NDA by year-end; the ongoing TARGET study will not be required for approval (1"The Pink Sheet" Nov. 12, 2001, p. 32)...

You may also be interested in...



Roche Fuzeon Dosing Convenience Is Challenge, Not Price – Physician Panel

The dosing convenience of Roche's injectable HIV drug Fuzeon could be one marketing challenge for the company, physician panelists predicted during a Banc of America-sponsored healthcare forum in New York City Dec. 11

Roche Fuzeon Dosing Convenience Is Challenge, Not Price – Physician Panel

The dosing convenience of Roche's injectable HIV drug Fuzeon could be one marketing challenge for the company, physician panelists predicted during a Banc of America-sponsored healthcare forum in New York City Dec. 11

Watson “Authorized” Generic Tri-Cyclen Will Share Market With Barr

Watson will launch an "authorized" generic version of Ortho-McNeil'soral contraceptive Ortho Tri-Cyclen when Barr enters the market with its generic under an agreement between Watson and Ortho announced Oct. 28

Related Content

UsernamePublicRestriction

Register

PS040667

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel